Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Apremilast (CC-10004) 是一种口服有效的磷酸二酯酶 4 抑制剂,IC50为 74 nM。它抑制脂多糖释放TNF-α,IC50为 104 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 452 | 现货 | ||
10 mg | ¥ 595 | 现货 | ||
25 mg | ¥ 725 | 现货 | ||
100 mg | ¥ 995 | 现货 | ||
200 mg | ¥ 1,520 | 现货 | ||
500 mg | ¥ 2,750 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | Apremilast (CC-10004) (CC-10004) is a potent and orally active PDE4 (IC50=74 nM) with anti-inflammation activities. |
靶点活性 | PDE4:74 nM |
体外活性 | Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM (pIC50=6.98±0.2), which almost exactly replicates previous reported TNF-α inhibition by Apremilast on peripheral blood mononuclear cells (PBMCs) (IC50=110 nM) and which is similar to the potency of Apremilast for PDE4 enzymatic inhibition (IC50=74 nM). These results are clearly consistent with the hypothesis that Apremilast inhibits TNF-α by increasing intracellular cAMP levels. PKA, Epac1 and Epac2 knockdowns prevented TNF-α inhibition and IL-10 stimulation by Apremilast[1]. |
细胞实验 | Apremilast is solubilized in DMSO and stored, and then diluted with appropriate media (DMSO 0.025%) before use[1]. Raw 264.7 cells (100,000) are grown in 96-well plates. After 24 h, cells are stimulated with vehicle (final concentration of 0.025% DMSO) or with Apremilast at the indicated concentrations. After 30 minutes cells are stimulated with LPS 1 μg/mL for 4 h. When studying CGS21680 , SCH58261, ZM241385, BAY60-6583, or GS6201, the adenosine receptor ligands are added 15 minutes before Apremilast. Methotrexate is added 24 h and 1 h before Apremilast. Supernates are then collected and TNF-α levels are quantified with the Mouse TNF-α Quantikine ELISA Kit. IC50 (EC50) calculations are made using non-linear regression, sigmoidal dose-response, constraining the top to 100 % and bottom to 0 %, allowing variable slope, using GraphPad Prism v6.00[1]. |
别名 | 阿普斯特, CC-10004, 阿普司特 |
化合物与蛋白结合的复合物 |
Crystal structure of PDE4D catalytic domain in complex with Apremilast |
分子量 | 460.5 |
分子式 | C22H24N2O7S |
CAS No. | 608141-41-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 92 mg/mL (199.78 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1716 mL | 10.8578 mL | 21.7155 mL | 54.2888 mL |
5 mM | 0.4343 mL | 2.1716 mL | 4.3431 mL | 10.8578 mL | |
10 mM | 0.2172 mL | 1.0858 mL | 2.1716 mL | 5.4289 mL | |
20 mM | 0.1086 mL | 0.5429 mL | 1.0858 mL | 2.7144 mL | |
50 mM | 0.0434 mL | 0.2172 mL | 0.4343 mL | 1.0858 mL | |
100 mM | 0.0217 mL | 0.1086 mL | 0.2172 mL | 0.5429 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Apremilast 608141-41-9 Apoptosis Metabolism TNF PDE TNFR orally TNF Receptor nucleotide inhibit lipopolysaccharide LPS phosphodiesterase CC 10004 PBMC Tumor Necrosis Factor Receptor CC10004 cyclic 阿普斯特 Phosphodiesterase (PDE) available CC-10004 阿普司特 Inhibitor type-4 inhibitor